Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Apr 2, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Albert Luderer will join Integrated Diagnostics' board of directors. Luderer recently was president and CEO of the molecular biology tools company BioTrove, which was acquired by Life Technologies a few months ago. Luderer also formerly was CEO of Light Sciences, president and chief operating officer of BioMerieux, and was involved in senior management at Boehringer Mannheim and Corning.

"Al's proven record in diagnostic development and commercialization will be essential to Integrated Diagnostics as we advance our diagnostics platform and develop the next generation of tools for diagnosing and preventing disease," Integrated Diagnostics Founder and Institute for Systems Biology President Leroy Hood said in a statement.

Response Genetics said this week that Thomas Stankovich has resigned from his position as chief financial officer, and he will leave the company by April 2. The company has begun searching for a new CFO, and has named Eric Alcorn, who is currently VP of finance and administration, to take on the CFO responsibilities in the interim.

Allen Bradley will step down from his role as director of the Wellcome Trust Sanger Institute, a position he has held since 2000, but he will continue working in mouse genetics at Sanger. The institute's deputy director and leader of the Cancer Genome project at Sanger, Mike Stratton, will replace Bradley as interim CEO.

Collin D'Silva will serve as president of Bruker's new Chemical Analysis division, which will operate under the firm's Bruker Daltonics subsidiary. The firm also said that D'Silva has resigned his positions on the firm's board of directors and audit committee.

Asuragen has appointed Lyle Arnold to serve on its board of directors. Arnold previously was VP of research at Gen-Probe, where he also was head of technology research in the late 1980s. He has worked in senior management and scientific positions at Molecular Biosystems, Genta, Synteni, Incyte Genomics, and Oasis Bioscience.

Orchid Cellmark said this week that Bruce Dalziel has joined the firm's board of directors. Dalziel currently is chief financial officer at Medidata Solutions, and he formerly was CFO for Bisys and for DoubleClick.

Steve Lincoln has joined Complete Genomics as vice president of scientific applications. Lincoln previously served as vice president of informatics at Affymetrix, executive vice president of product development and CSO of InforMax, and vice president of bioinformatics R&D at Incyte.

Daniel Von Hoff, physician-in-chief for the Translational Genomics Research Institute has been awarded the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his cancer research.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.